Drug Price Trends for REBIF

Average Pharmacy Cost for REBIF

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
REBIF 44 MCG/0.5 ML SYRINGE	44087-0044-03	1849.88373	ML	2026-01-03
REBIF REBIDOSE 44 MCG/0.5 ML	44087-3344-01	1848.67278	ML	2026-01-03

Market Analysis and Price Projections for REBIF

Last updated: February 12, 2026

Overview
REBIF (interferon beta-1a) is a biologic therapy produced by Serono (a division of Merck KGaA) used primarily for multiple sclerosis (MS) and potentially other autoimmune disorders. It has been on the market since 1996, making it a mature product with established manufacturing, distribution channels, and competitive landscape. The market for MS biologics is significant, driven by increasing prevalence, expanding indications, and evolving treatment guidelines.

Market Size and Revenue Trends
Globally, the multiple sclerosis market was valued at approximately USD 24.5 billion in 2021. REBIF accounted for an estimated USD 1.2 billion in sales in 2022, representing about 5% of the total MS biologics market. The drug's market share has declined compared to peak years (approximately 2.5% of the entire MS market in 2005) due to entries of newer therapies.

Key factors influencing market size:

• MS prevalence: Estimated at 2.8 million globally, with rising cases due to increased awareness and diagnostics.
• Treatment penetration: Approximately 50-55% of MS patients are on disease-modifying therapies (DMTs), with biologics comprising roughly 35-40% of DMT utilization.
• Competitive pipeline: Several new biologics and oral agents have entered the market, often at lower costs and with different efficacy and safety profiles.

Competitive Landscape
REBIF faces competition mainly from:

• MS biologics: Avonex (also interferon beta-1a), Betaseron/Bonviva (interferon beta-1b), Tysabri (natalizumab), Lemtrada (alemtuzumab).
• Oral therapies: Novartis’s Gilenya (fingolimod), Bristol-Myers Squibb’s Opdivo, and others.

Market share is shifting toward oral agents and newer biologics due to convenience and perceived superiority in efficacy or safety profiles. REBIF’s generic and biosimilar advents could further affect future sales.

Pricing and Pricing Trends
In the US, list prices for REBIF have varied over the years:

Year	Approximate Annual Price per 22 mcg Refill	Notes
2010	USD 45,000	Brand pricing peak
2015	USD 50,000	Slight increase, inflation-adjusted
2020	USD 40,000–45,000	Price stabilization, biosimilar presence
2022	USD 42,000	Manufacturer discounts common

| International Pricing | Variability by country | Lower in Europe (roughly 60–70%) | Due to payers' negotiations and formulary control |

Regulatory and Policy Factors Affecting Price

• US: The 2020 Pharmacy Benefit Manager (PBM) negotiations and Medicaid rebates depress net prices.
• Europe: Pricing negotiations are conducted at the country level; discounts of up to 40% are common.
• Biosimilar Impact: The first biosimilar interferon beta-1a launched in 2019 in Europe reduced patients' access costs, leading to price pressures.

Price Projections
Over the next five years, price trends are expected to decline modestly:

• US: Net prices may decline by 10–20% due to biosimilars and payer negotiations.
• Europe and Other Markets: Similar reductions, influenced by national reimbursement policies and competitive biosimilar uptake.

Forecast Scenarios:

• Conservative: 5% annual decline in net price, volume growth of 2–3% driven by increased MS diagnosis rates.
• Aggressive: 10% annual decline driven by biosimilar penetration and market share shifts, with volume growth limited or stagnant.

Potential Catalysts and Risks

• New Indications: Expansion into pediatric MS or other autoimmune conditions can expand market size.
• Patent and Biosimilar Competition: Loss of exclusivity in key markets (US 2025, Europe 2026) can accelerate price erosion.
• Market Dynamics: Preference for oral therapies diminishes demand for injectable biologics like REBIF.

Key Takeaways

• REBIF remains a relevant MS biologic with consistent sales but faces declining prices due to biosimilar entry and market shift toward oral therapies.
• US net prices are expected to decline 10–20% over five years amid competitive pressure.
• European prices may decrease by 40–50% with biosimilar adoption.
• Market growth depends on increased diagnosis and potential new indications but constrained by biosimilar competition.
• Heightened payer attention and policy changes can accelerate price compression.

FAQs

1. What is the current patent status of REBIF?
   The original patents expired in the US in 2015, with patent protections in Europe ending around 2016–2018. New formulations or delivery devices may have separate patent protections.

2. How do biosimilars impact REBIF’s market?
   Biosimilars launched in Europe in 2019 caused significant price reductions, with subsequent adoption reducing REBIF’s market share.

3. Are there upcoming regulatory approvals for REBIF?
   No recent approvals are announced; the focus is on biosimilar competition and market penetration.

4. What markets offer the highest growth potential for REBIF?
   Emerging markets with increasing MS diagnosis, such as Asia-Pacific, may offer growth opportunities if pricing and reimbursement conditions improve.

5. How does REBIF compare with newer MS treatments?
   Newer biologics and oral agents often demonstrate higher efficacy or convenience, reducing REBIF’s competitive appeal but retaining a foothold in patients preferring injectable therapies.

---

Sources

1. GlobalData. "Multiple Sclerosis Therapeutics Market Analysis," 2022.
2. IQVIA. "IMS Health Weekly Drug Price Trends," 2022.
3. European Medicines Agency. "REBISET (interferon beta-1a) Summary," 2021.
4. U.S. FDA. "Biologic Licensing Applications," 2022.
5. MarketWatch. "MS Drug Market Outlook," 2022.